New England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. DPZ
4. ACN
5. DFTX
6. IBM
7. META
8. AISP
9. KFY
10. SPY

Go back to New England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease

Goldman Sachs Remains Bullish on BioMarin Pharma (BMRN) Following 1Q

April 26, 2018 8:12 AM EDT

Goldman Sachs reiterated a Buy rating and $132.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following the company's 1Q earnings release. BMRN reported total revenue of $373.4mn, above FactSet consensus of $349mn, driven primarily by the adoption of the new revenue recognition principle for... More